Form 4: Jasper Therapeutics COO Exercises Options and Sells Shares Under 10b5-1 Plan

Jeetinder Singh Mahal, COO of Jasper Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jeetinder Singh Mahal, the Chief Operating Officer of Jasper Therapeutics, Inc., executed transactions involving the company's voting common stock on September 12, 2024.
• Mahal exercised stock options to acquire 900 shares at a price of $7.10 per share.
• Concurrently, Mahal sold 900 shares at a weighted average price of $21.2263, with individual sales ranging from $20.795 to $21.495.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on March 15, 2023.
• Following these transactions, Mahal directly owns 25,009 shares of voting common stock and holds options for 14,672 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy. There's no indication of positive or negative implications for the company's performance.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the 10b5-1 plan provides some protection, significant insider selling could still be perceived negatively by the market.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of 10b5-1 plans is common for executives to manage their stock holdings while avoiding accusations of insider trading.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on their perception of insider selling, even under a 10b5-1 plan.

Key Dates